If a nootropic peptide such as Semax or Selank made you foggier instead of sharper, the most likely cause is not the peptide. Work through the changeable causes first: sleep debt you cannot feel, the amount, the time of day, other stimulants already on board, whether a calming compound was taken for a focus problem, and what is actually in an unverified vial. Individual differences explain what is left, and the mechanism is direction-dependent: in a randomised double-blind trial, 67 healthy men were split by a single gene variant and randomised to a 200 mg dose of a drug that blocks dopamine clearance from the prefrontal cortex or to placebo, and the drug improved working memory in the fast-clearing group while worsening it in the slow-clearing group, reversing the gap seen on placebo.
If a peptide sold for sharper thinking left you foggier, the most likely cause is not the peptide. Six of the seven usual explanations are things you can measure or change inside a week: sleep debt you cannot feel, an amount above anything a published protocol used, an evening dose, caffeine or a prescribed stimulant already on board, a calming compound taken for a focus problem, and a vial nobody verified. The seventh, how fast your own brain clears dopamine, is the only one you cannot change, and it is last on the list for that reason. If terms like reconstitution or research-channel vial are new, start at /learn/peptides-for-beginners and come back.
Why do peptides make me foggy?
Fog on a nootropic peptide has an ordered list of suspects, and the top of that list is dull. Work down it before anyone gets to talk about your DNA, because the first six causes are things you can measure or change in a week and the seventh is a fixed trait you cannot. The ranked list of which compounds are worth trying at all sits in the brain fog roster at /learn/best-peptides-for-brain-fog, and the compound-by-compound evidence for focus sits at /peptides-for/focus. This page answers a narrower question: why the same compound at the same amount lands so differently on different people.
- Count your sleep before you blame the compoundSleep loss is the single largest confounder in any self-experiment on cognition. Van Dongen and colleagues randomised healthy adults aged 21 to 38 to 4, 6 or 8 hours in bed a night for 14 consecutive nights and found cumulative, dose-dependent deficits on every cognitive task at 4 and 6 hours. Self-rated sleepiness did not separate the 6-hour group from the 4-hour group. That randomisation sat inside a 48-participant programme which also ran a separate 3-night total sleep deprivation arm [[2]]. If you started a compound during a bad fortnight of sleep, the compound is the least likely explanation for how you feel.
- Check whether the fog arrived with an increaseThe sequence matters more than the number. If a week went fine and the fog started when you went up, the amount is the variable that changed, and it is where the conversation with a clinician starts. In the published Semax work, stroke patients in the treated subgroups received 6,000 mcg a day [[6]]. The amounts discussed for everyday focus are far lower and have never been through a trial with a focus endpoint, so there is no established range to compare yourself against.
- Check the clockSemax has a short reported effect window, and late doses are the most common complaint in user reports, which are anecdote and not measurement. Even an early-afternoon dose can cost an hour of sleep, and an hour of sleep buys a foggy tomorrow that reads as the compound failing. Cycling and timing mechanics are covered at /learn/peptide-cycling-protocol.
- Count everything else that is already stimulating youCaffeine, nicotine and prescribed stimulants such as methylphenidate all push the same general direction. No formal interaction study exists for Semax with any of them, which means nobody has looked, not that anyone found it safe. If you added a compound on top of an existing stimulant load, you changed two things at once and cannot read the result.
- Ask whether you took a calming compound for a focus problemSelank is discussed for anxiety-driven distraction, where worry hijacks attention, and its reported effect is calming. Someone whose problem is slow cognitive output can take Selank, feel flatter, and call that brain fog. The only placebo-controlled work in healthy adults gave Selank, Semax or placebo to 52 participants and measured resting-state brain connectivity, not symptoms and not performance [[8]]. Match the compound to the pattern: the anxiety pattern is covered at /peptides-for/anxiety, and Selank itself at /peptides/selank.
- Consider what is in the vialResearch-channel peptides are not verified by any regulator, so nobody has confirmed the identity, the amount or the sterility of what you reconstituted. This is not hypothetical. Belgian public health analysts identified Selank and Semax in seized, unlabelled preparations sold online as powders for injection and as nasal sprays, and noted that neither peptide has completed any clinical trial [[9]]. Reconstitution errors are their own category: a miscalculated dilution changes the delivered amount by a multiple, not a percentage. If you cannot say who made what you injected, that is the thing to fix before you change anything else. Vendor testing and third-party assay practices are compared at /compare, sterile handling is at /learn/peptide-injection-hygiene-guide, and if you are already using a compound the arithmetic behind dilution errors is explained at /learn/how-to-reconstitute-peptides. That page describes the maths; it is not an instruction to obtain or use anything.
Example: 6 hours of sleep a nighthours in bed per night
What the published protocols used
These are the studies this page rests on, and the last row is the one most people assume already exists. Read the who-or-what-was-studied column first: two of the five rows are not humans, or not a peptide.
| Study | What was given | Route and duration | Who or what was studied | What it showed |
|---|---|---|---|---|
| Dolotov 2006 5 | Semax, 50 and 250 mcg per kg of bodyweight | Intranasal, single dose, measured at 3 hours | Rats | BDNF protein rose in the basal forebrain, a region that feeds attention circuits, and did not rise in the cerebellum |
| Gusev 2018 6 | Semax, 6,000 mcg a day in the treated subgroups | Two 10-day courses 20 days apart; the published abstract does not state the route | 110 people recovering from ischaemic stroke, mean age 58, split into treated and untreated subgroups. Not randomised, not blinded, no placebo arm | BDNF in blood rose and stayed up, and the Barthel index, a score of how independently a person manages daily tasks, improved faster in the treated subgroups |
| Panikratova 2020 8 | Semax, Selank or placebo | Single injection, scanned before and at 5 and 20 minutes | 52 healthy participants | Resting-state connectivity between the right amygdala and the right temporal cortex changed. No attention, memory or focus performance was measured |
| Farrell 2012 1 | 200 mg tolcapone, a prescription Parkinson's drug rather than a peptide. Tolcapone carries an FDA boxed warning for fatal liver injury and requires liver-enzyme monitoring; it is named here only as the tool that demonstrated the direction-of-effect principle | Single oral dose, randomised, double-blind, placebo-controlled | 67 healthy men, 34 Met/Met and 33 Val/Val, grouped by how fast they clear dopamine and then randomised to drug or placebo | Working memory improved in the fast-clearing group and worsened in the slow-clearing group, reversing the difference seen on placebo |
| No trial with a focus endpoint | Semax or Selank for focus or brain fog | n/a | Healthy adults (brain-imaging endpoints only) | No placebo-controlled trial with an attention or focus performance endpoint is indexed on PubMed for either compound |
Can nootropics cause brain fog even at a sensible amount?
Yes, and the mechanism is well characterised in humans, though not for peptides. Dopamine, the chemical that carries reward and focus signals, does not follow a more-is-better curve in the prefrontal cortex, the part of the brain that holds several things in mind at once. Performance rises with dopamine to a peak and then falls off. Someone sitting below the peak gets sharper from a push. Someone already near it gets pushed over, and being over the peak feels like being wired and scattered at the same time. The enzyme that clears dopamine out of the prefrontal cortex is called COMT, and the drug used in the trial below, tolcapone, blocks it.
Depending on genotype, COMT inhibition can enhance or impair working memory and increase or decrease risky decision making. To our knowledge, the data are the clearest demonstration to date that the direction of effect of a drug can be influenced by a polymorphism in its target gene.Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ. Biological Psychiatry, 2012 [[1]]
That trial used a prescription drug, not a peptide, and it enrolled 67 men who were grouped by genotype and then randomised to drug or placebo, so roughly half of each group actually took tolcapone. It is not evidence about Semax. What it establishes is the principle a foggy reader needs: a compound that raises dopamine has a direction of effect that depends on where the person started, so two people can take the identical thing and report opposite results without either of them being wrong or unlucky.
What individual differences explain, and what they do not
Three variants get named constantly in brain fog discussions. Two of them describe something real about brain chemistry. The third does not belong in the conversation at all, and in the table below its row for what you would do differently is, honestly, nothing.
| What varies | What it does, in plain words | What the evidence supports | What you would do differently knowing it |
|---|---|---|---|
| How fast the front of the brain clears dopamine (COMT rs4680) | COMT is the enzyme that mops dopamine out of the prefrontal cortex. The Met version works several times slower than the Val version, so dopamine lingers longer between signals. | A COMT-blocking drug reversed the baseline genotype difference in working memory in a randomised double-blind trial 1. | Expect a direction, not only a size. A bad first week is information, not noise. It does not tell you what to change, and any change belongs with a clinician who knows your history. |
| How much growth factor a firing neuron releases (BDNF rs6265) | BDNF is the protein neurons release to build and keep connections. The Met version is not packed into the release granules properly, so neurons release less of it when they fire. | Egan and colleagues showed the packaging failure in transfected neurons, and Met carriers had poorer episodic memory and altered hippocampal activity on brain imaging 3. | Set a lower ceiling on your expectations for anything whose proposed mechanism is raising BDNF. Know that before you spend the money. |
| Folate processing (MTHFR C677T) | MTHFR is an enzyme that converts dietary folate into the form the body can use. The T version works less well and pushes up homocysteine, a blood marker that rises when folate runs low. | The American College of Medical Genetics and Genomics concluded that testing this polymorphism has minimal clinical utility and should not be ordered as part of a routine thrombophilia evaluation 4. | Nothing, for this question. Adequate dietary folate is standard advice for everyone regardless of genotype, and the variant is not a diagnosis. |
No trial has ever tested any peptide against any of those three variants, so nothing in that last column is a dosing rule. What you have is a reason to expect a direction and a reason to keep your expectations modest.
Association is not prediction. A variant that shifts the odds across thousands of people still tells you very little about the next fortnight of your own life.
Why does Semax not work for me?
Because it may not improve focus in a healthy adult at all, which no trial has ever tested. The mechanism most often quoted for Semax, whose entity page sits at /peptides/semax, is that it raises BDNF, and that finding comes from rat basal forebrain tissue three hours after an intranasal dose 5. The strongest human record is unblinded stroke rehabilitation work in Russia, comparing patients who received semax against patients who did not, with no placebo arm: the treated subgroups got 6,000 mcg a day across two 10-day courses and showed higher BDNF in blood and faster gains in daily function 6. Placebo-controlled work in healthy adults exists and measured brain-network connectivity 20 minutes after a single injection, not attention and not performance 8. Semax is registered in Russia and listed there for cerebrovascular and neurological use. It has never been approved by the FDA or the EMA, has never been through a Western phase 3 trial, and most of its supporting literature is published in Russian and has not been independently replicated.
Non-response is therefore an ordinary outcome with an ordinary explanation, and the hierarchy above is where to look for it. A compound with no human focus trial has no established response rate to fall short of.
Matching the compound to the pattern
| What the fog feels like | What gets discussed for it | Evidence tier | US regulatory status |
|---|---|---|---|
| Slow, effortful thinking with steady mood and no gut symptoms | Semax | Rat BDNF data 5, unblinded Russian stroke work in people 6, and one placebo-controlled brain-imaging study in healthy adults with no performance endpoint 8. No focus trial in healthy adults. | Not FDA-approved. Off Category 2 since 22 April 2026, never added to Category 1, so compounding is not authorised. |
| Attention hijacked by worry and rumination | Selank | Russian anxiety literature, largely unreplicated in the West. The one placebo-controlled study in healthy adults measured brain connectivity, not anxiety and not attention 8. | Not FDA-approved. Still on the FDA's Category 2 list, so US compounding pharmacies cannot prepare it. |
| Fog that tracks gut symptoms or began after an infection (see /peptides-for/gut-healing) | BPC-157 | No study has examined BPC-157 for cognitive symptoms of any kind. The nearest systematic review is orthopaedic: 544 articles screened, 36 included, 35 preclinical and 1 clinical, a retrospective series of 12 patients with knee pain 7. | Not FDA-approved. Off Category 2 since 22 April 2026 but never added to Category 1. A July 2026 advisory committee vote to add it was non-binding and no rulemaking has followed. |
If none of the three above matches your pattern, the honest answer may be that no peptide is the right tool for it: the ranked version, including which options are not worth the money, is at /learn/best-peptides-for-brain-fog, and if the fog tracks your sleep instead of your dosing, /peptides-for/sleep is the better starting point.
What your raw DNA file can settle here, and what it cannot
Both variants that matter to this page, COMT rs4680 and BDNF rs6265, are common enough that consumer genotyping arrays generally carry them, so a 23andMe or AncestryDNA raw file will usually show you what you carry at those two positions. That is the limit of what the file does on its own.
A 23andMe file reads about 640,000 preselected positions out of roughly 3 billion base pairs, so it can tell you what you carry at a spot it looked at and nothing about a spot it did not.
If you have never opened your raw file, /learn/23andme-peptide-guide walks through downloading it and finding a single position inside it. Knowing your dopamine-clearance genotype changes your expectations and your caution in the first week. It does not set an amount, because no peptide covered on this site has a validated pharmacogenomic dosing rule of the kind that exists for warfarin, the blood thinner whose dose genuinely is adjusted by genotype. Where genetics sits in the order of decisions is laid out in /learn/which-peptides-dna-decision-framework, and how our panel scores all 39 peptides against a raw file is at /methodology.
Link · Farrell et al., Biological Psychiatry, 2012 (PMID 22364739)COMT Val158Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibitionThe double-blind trial behind this page. 34 Met/Met and 33 Val/Val men, grouped by genotype and randomised to one 200 mg dose of tolcapone or placebo, with N-back working memory and a gambling task. Tolcapone reversed the baseline genotype difference in both tasks.pubmed.ncbi.nlm.nih.govUpload your raw DNA data and see how your own variants line up against the compounds discussed for focus. All 39 peptides are sorted against your file, with the evidence tier shown for each. The report is educational, is not a diagnostic test, and does not recommend a compound or an amount: no peptide has a validated genotype-based dosing rule.
Get your DNA report- The changeable causes outrank the fixed ones
Six of the seven common explanations for fog on a nootropic peptide are things you can measure or change within a week. Genotype is the seventh and the only fixed one, so it is the last place to look, not the first. It matters when it matters because a dopamine push has a direction and not only a size: in a randomised double-blind trial, one 200 mg dose of a dopamine-clearance blocker improved working memory in the fast-clearing genotype group and worsened it in the slow-clearing group, reversing the gap seen on placebo. Even then a variant sets expectations and never an amount, because no peptide has ever been tested against a genotype.
Sources9
- Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ. COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biological Psychiatry, 2012;71(6):538-44 (67 healthy men, 34 Met/Met and 33 Val/Val, grouped by genotype and randomised double-blind to a single 200 mg tolcapone dose or placebo; erratum Biol Psychiatry 2015;77(3):304 corrects table headings only).
- Van Dongen HP, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep, 2003;26(2):117-26 (48 healthy adults across both experiments: 14 nights randomised to 4, 6 or 8 hours in bed, plus a separate 3-night total sleep deprivation arm).
- Egan MF et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 2003;112(2):257-69.
- Hickey SE, Curry CJ, Toriello HV. ACMG practice guideline: lack of evidence for MTHFR polymorphism testing. Genetics in Medicine, 2013;15(2):153-6 (conclusion scoped to routine thrombophilia evaluation).
- Dolotov OV et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 2006;97 Suppl 1:82-6 (intranasal 50 and 250 mcg/kg, rats).
- Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova, 2018;118(3 Vyp 2):61-68 (110 patients divided into treated and untreated subgroups, 6,000 mcg/day in the treated subgroups across two 10-day courses; not randomised, not blinded, no placebo arm; Russian language).
- Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025 (544 articles screened, 36 included: 35 preclinical, 1 clinical; orthopaedic endpoints only, no cognitive or gastrointestinal outcome).
- Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV, Myasoedov NF. Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 2020;490(1):9-11 (52 healthy participants, single injection of Semax, Selank or placebo, resting-state fMRI before and at 5 and 20 minutes; amygdala and DLPFC regions of interest, no cognitive performance endpoint).
- Vanhee C, Francotte A, Janvier S, Deconinck E. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: an incentive for controlling agencies to prepare for future encounters of the kind. Drug Testing and Analysis, 2020;12(3):371-381 (Selank and Semax identified in seized unlabelled preparations; peptides sold online as lyophilised powder for injection and as nasal sprays, none having completed clinical trials).
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.
Frequently asked questions
Why do peptides make me foggy?
Most often because of something other than the peptide's mechanism. Sleep debt is the largest confounder: healthy adults held at 6 hours in bed for 14 nights developed cognitive deficits equivalent to up to two nights of total sleep deprivation, and their own sleepiness ratings did not track the decline (Van Dongen 2003, PMID 12683469). After that come an increase in the amount used, a late dose that costs sleep, stacking on top of caffeine or a prescribed stimulant, taking a calming compound like Selank for a problem of slow cognitive output, and unverified vial contents, since no regulator checks research-channel peptides and analysts have found Selank and Semax in seized unlabelled preparations (Vanhee 2020, PMID 31667971). Individual differences in dopamine clearance explain the cases that survive that checklist.
Can nootropics cause brain fog?
Yes, and the clearest human demonstration involves a prescription drug, not a peptide. Farrell and colleagues grouped 67 healthy men by how fast they clear dopamine, then randomised them double-blind to a single 200 mg dose of tolcapone, which blocks the enzyme that clears dopamine from the prefrontal cortex, or to placebo. Working memory improved in the fast-clearing group and worsened in the slow-clearing group, reversing the difference seen on placebo (PMID 22364739). Performance follows an inverted-U against prefrontal dopamine, so a push helps people below the peak and hurts people already near it. Tolcapone is prescription-only and carries an FDA boxed warning for fatal liver injury; it is mentioned only because it demonstrated the principle. No trial has tested this with any peptide.
Why does Semax not work for me?
There is no established response rate for Semax to fall short of, because no placebo-controlled trial has measured focus or attention performance with it in healthy adults. Its BDNF mechanism comes from rat basal forebrain tissue (Dolotov 2006, PMID 16635254). Its strongest human record is unblinded stroke rehabilitation in Russia, where 110 patients were split into treated and untreated subgroups with no placebo arm, and the treated subgroups received 6,000 mcg a day across two 10-day courses (Gusev 2018, PMID 29798983). The one placebo-controlled study in healthy adults gave Semax, Selank or placebo to 52 people and scanned brain-network connectivity rather than testing performance (Panikratova 2020, PMID 32342318). Semax is registered in Russia and has never been approved by the FDA or the EMA. Non-response is an ordinary outcome, and sleep, timing, stacking and vial contents are the first places to look.
Is it true that 1 in 4 people get brain fog from Semax?
No. That figure appeared in an earlier version of this page and no study supports it. It was borrowed from an approximate genotype frequency for slow dopamine clearance and reused as though it were a side-effect rate, which are different quantities. No published study has measured how often brain fog occurs on Semax in any population, because no placebo-controlled trial with a cognitive performance endpoint in healthy adults exists to measure it in.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.